English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
インデックス付き
- Google スカラー
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- パブロン
- ICMJE
役立つリンク
オープンアクセスジャーナル
このページをシェアする
抽象的な
Is Endocan a Novel Prognostic Marker for Colorectal Cancer?
Korkmaz UB , Akyol M , Alacacioglu A , Salman T *, Varol U , Küçükzeybek Y , Oflazoglu U and Uzum Y
Purpose: The present study aimed to investigate the relationship between pretreatment serum Endocan levels and pretreatment serum VEGF levels in colorectal cancer cases, as well as colorectal cancer prognosis. Methods: This study included a control group of 16 individuals and a patient group of 67 cases with colorectal cancer. Serum VEGF and Endocan levels were determined with enzyme-linked immunosorbent assay (ELISA) kits used for scientific research purposes. Results: The examinations showed no significant relations between serum endocan level and prognosis. Also, no significant difference was detected between the patient group and control group in terms of height, weight, age or BMI levels. The examinations indicated no significant difference between the groups except for the VEGF level. VEGF levels in metastatic colorectal cancer cases were significantly higher than the control group and the tumor-free colorectal cancer cases (p: 0.005, p: 0.038; respectively). Conclusion: This study showed that there was no significant relationship between pretreatment Endocan levels and VEGF levels, as well as prognosis.